Related Experiment Video

Updated: Jun 27, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease

G A Jicha1, F A Schmitt, E Abner

  • 1Department of Neurology, University of Kentucky College of Medicine, Lexington, KY 40536, USA. gajich2@email.uky.edu

Neurobiology of Aging
|November 26, 2008
PubMed

Insights

Mild cognitive impairment in dementia with Lewy bodies (MCI-DLB) can be distinguished from Alzheimer

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • The early stages of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) present diagnostic challenges.
  • Mild cognitive impairment (MCI) is a preclinical stage for both neurodegenerative diseases.
  • Distinguishing MCI due to DLB (MCI-DLB) from MCI due to AD (MCI-AD) is crucial for timely intervention.

Purpose of the Study:

  • To investigate clinical features that differentiate MCI-DLB from MCI-AD.
  • To assess the feasibility of early detection of prodromal DLB and AD.

Main Methods:

  • Comparison of clinical data from 9 neuropathologically confirmed MCI-DLB cases and 12 MCI-AD cases.
  • Analysis of demographic, clinical, and cognitive variables between the two groups.

Main Results:

  • No significant differences in age, gender, ApoE status, education, or disease duration were found.
  • MCI-DLB cases showed a higher prevalence of Parkinsonism and provoked hallucinations/delirium compared to MCI-AD.
  • Letter fluency was lower and logical memory scores were higher in MCI-DLB versus MCI-AD.

Conclusions:

  • Clinical features, particularly non-cognitive symptoms, can help distinguish MCI-DLB from MCI-AD.
  • These findings support the potential for refining diagnostic criteria for early detection of prodromal DLB and AD.
  • Differentiating underlying pathologies in preclinical stages is feasible, aiding in earlier diagnosis and management.

More Related Videos

Technique for Intranasal Administration of α-Synuclein Aggregates04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...